Summary
This 8-K filing by Gilead Sciences, Inc. (GILD) on February 21, 2017, primarily details compensation arrangements for its Executive Chairman, John C. Martin, Ph.D. The key takeaway for investors is the setting of Dr. Martin's 2017 base salary at $1,160,000. Additionally, he was granted stock options and performance share awards, each with a grant-date fair value of $2,000,000, effective February 16, 2017. The performance share awards are structured with a total shareholder return (TSR) tranche and a revenue tranche, with both components weighted at 50% of the award's fair value. The performance metrics and structure for these awards are substantially similar to those granted in 2016, indicating a continuation of the company's approach to executive incentive compensation. Investors should note that the specific number of shares and exercise price for the options will be determined by the company's stock price on the effective grant date.
Key Highlights
- 1John C. Martin, Ph.D., Executive Chairman, has a 2017 base salary set at $1,160,000.
- 2Dr. Martin received stock options with a grant-date fair value of $2,000,000.
- 3Dr. Martin also received performance share awards with a grant-date fair value of $2,000,000.
- 4The performance share awards are split 50/50 between a Total Shareholder Return (TSR) tranche and a revenue tranche.
- 5The revenue tranche of the performance shares is divided into three separate annual subtranches.
- 6Stock options will have an exercise price equal to the closing price of GILD common stock on February 16, 2017.
- 7The compensation arrangements are designed to incentivize executive performance and align with shareholder interests.